<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Hepsera, INN-adefovir dipivoxil</title>

<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	line-height:13.0pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;}
h6
	{mso-style-link:"Heading 6 Char";
	margin:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:normal;
	font-style:italic;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Annotationtext";
	mso-style-link:"Comment Text Char\,Annotationtext Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:normal;
	font-size:10.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:normal;
	font-size:8.0pt;
	font-family:"Helvetica",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Cambria",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:justify;
	line-height:normal;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Cambria",serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin:0in;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;
	text-decoration:underline;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin:0in;
	text-align:justify;
	line-height:normal;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:blue;
	font-weight:bold;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:31.65pt;
	text-align:justify;
	line-height:13.0pt;
	text-autospace:none;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:13.0pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	margin-bottom:.0001pt;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:35.4pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:10.0pt;
	margin-right:.65in;
	margin-bottom:14.0pt;
	margin-left:.65in;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Cambria",serif;
	font-weight:bold;
	font-style:italic;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Cambria",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Calibri",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Calibri",sans-serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Calibri",sans-serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Calibri",sans-serif;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Cambria",serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Annotationtext Char";
	mso-style-link:"Comment Text\,Annotationtext";}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;}
p.AHeader1, li.AHeader1, div.AHeader1
	{mso-style-name:"AHeader 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	line-height:normal;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2, li.AHeader2, div.AHeader2
	{mso-style-name:"AHeader 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:35.45pt;
	text-indent:-21.25pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader3, li.AHeader3, div.AHeader3
	{mso-style-name:"AHeader 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.AHeader2abc, li.AHeader2abc, div.AHeader2abc
	{mso-style-name:"AHeader 2 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:63.8pt;
	text-align:justify;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.AHeader3abc, li.AHeader3abc, div.AHeader3abc
	{mso-style-name:"AHeader 3 abc";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:85.05pt;
	text-align:justify;
	text-indent:-21.25pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
p.Text1, li.Text1, div.Text1
	{mso-style-name:"Text 1";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-weight:bold;}
p.SPCList, li.SPCList, div.SPCList
	{mso-style-name:SPC_List;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:85.05pt;
	text-indent:-28.35pt;
	line-height:normal;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.EmailStyle45
	{mso-style-name:EmailStyle45;
	font-family:"Arial",sans-serif;
	color:windowtext;}
span.CommentTextChar1
	{mso-style-name:"Comment Text Char1";}
p.Tableleftbold, li.Tableleftbold, div.Tableleftbold
	{mso-style-name:"Table left bold";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:normal;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#4F81BD;
	font-weight:bold;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Cambria",serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:black;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Cambria",serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Cambria",serif;
	font-weight:bold;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1.       NAME OF THE
MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepsera
10&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.       QUALITATIVE AND
QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 10&nbsp;mg adefovir dipivoxil.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
page-break-after:avoid;text-autospace:none'><u><span lang=EN-GB>Excipient(s)
with known effect:</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 113&nbsp;mg lactose monohydrate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full
list of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.       PHARMACEUTICAL <span
style='text-transform:uppercase'>form</span></span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>White to off&#8209;white,
round, flat&#8209;faced, bevelled&#8209;edge tablets, 7&nbsp;mm in diameter,
debossed with GILEAD and 10 on one side and a stylised shape of a liver on
the other side.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4.       Clinical
particulars</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1     Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepsera is
indicated for the treatment of chronic hepatitis&nbsp;B in adults with:</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>compensated liver disease with evidence of
active viral replication, persistently elevated serum alanine aminotransferase
(ALT) levels and histological evidence of active liver inflammation and
fibrosis.  Initiation of Hepsera treatment should only be considered when the
use of an alternative antiviral agent with a higher genetic barrier to
resistance is not available or appropriate (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>decompensated liver disease in combination with
a second agent without cross-resistance to Hepsera.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.2     Posology and method
of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Therapy should
be initiated by a physician experienced in the management of chronic
hepatitis&nbsp;B.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Adults:</span></i><span
lang=EN-GB> The recommended dose of Hepsera is 10&nbsp;mg (one tablet) once
daily taken orally with or without food.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Higher doses
must not be administered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The optimum
duration of treatment is unknown.  The relationship between treatment response
and long&#8209;term outcomes such as hepatocellular carcinoma or decompensated
cirrhosis is not known.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
decompensated liver disease, adefovir should always be used in combination with
a second agent, without cross-resistance to adefovir, to reduce the risk of
resistance and to achieve rapid viral suppression.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients should
be monitored every six months for hepatitis&nbsp;B biochemical, virological and
serological markers.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Treatment discontinuation may be considered as follows:</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        In HBeAg&nbsp;positive patients without
cirrhosis, treatment should be administered for at least 6&#8209;12&nbsp;months
after HBe&nbsp;seroconversion (HBeAg&nbsp;loss and HBV&nbsp;DNA loss with anti&#8209;HBe&nbsp;detection)
is confirmed or until HBs&nbsp;seroconversion or there is loss of efficacy
(see&nbsp;section&nbsp;4.4).  Serum ALT and HBV&nbsp;DNA levels should be
followed regularly after treatment discontinuation to detect any late
virological relapse.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        In HBeAg&nbsp;negative patients without
cirrhosis, treatment should be administered at least until
HBs&nbsp;seroconversion or there is evidence of loss of efficacy.  With
prolonged treatment for more than 2&nbsp;years, regular reassessment is
recommended to confirm that continuing the selected therapy remains appropriate
for the patient.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
decompensated liver disease or cirrhosis, treatment cessation is not
recommended (see&nbsp;section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Special populations</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly:</span></i><span
lang=EN-GB> No data are available to support a dose recommendation for patients
over the age of 65&nbsp;years (see&nbsp;section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal impairment:</span></i><span
lang=EN-GB> Adefovir is eliminated by renal excretion and adjustments of the
dosing interval are required in patients with a creatinine clearance
&lt;&nbsp;50&nbsp;ml/min or on dialysis.  The recommended dosing frequency
according to renal function must not be exceeded (see&nbsp;sections&nbsp;4.4
and 5.2).  The proposed dose interval modification is based on extrapolation of
limited data in patients with end stage renal disease (ESRD) and may not be
optimal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Patients with creatinine clearance between 30 and 49&nbsp;ml/min:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is
recommended to administer adefovir dipivoxil (one 10&nbsp;mg tablet) every 48&nbsp;hours
in these patients.  There are only limited data on the safety and efficacy of
this dosing interval adjustment guideline.  </span><span lang=EN-GB>Therefore,
clinical response to treatment and renal function should be closely monitored
in these patients (see&nbsp;section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Patients with creatinine clearance &lt;&nbsp;30&nbsp;ml/min and
dialysis patients:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
safety and efficacy data to support the use of adefovir dipivoxil in patients
with a creatinine clearance &lt;&nbsp;30&nbsp;ml/min or on dialysis. 
Therefore, use of adefovir dipivoxil is not recommended in these patients and
should only be considered if the potential benefits outweigh the potential
risks.  In that case, the limited data available suggest that for patients with
creatinine clearance between 10 and 29&nbsp;ml/min, adefovir dipivoxil (one
10&nbsp;mg tablet) may be administered every 72&nbsp;hours; for haemodialysis
patients, adefovir dipivoxil (one 10&nbsp;mg tablet) may be administered every
7&nbsp;days following 12&nbsp;hours continuous dialysis (or 3&nbsp;dialysis
sessions, each of 4&nbsp;hours duration).  These patients should be closely
monitored for possible adverse reactions and to ensure efficacy is maintained
(see&nbsp;sections&nbsp;4.4 and 4.8).</span><span lang=EN-GB>  </span><span
lang=EN-GB>No dosing interval recommendations are available for other dialysis
patients (e.g. ambulatory peritoneal dialysis patients) or non&#8209;haemodialysed
patients with creatinine clearance less than 10&nbsp;ml/min.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic
impairment:</span></i><span lang=EN-GB> No dose adjustment is required in
patients with hepatic impairment (see&nbsp;section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Clinical
resistance:</span></i><span lang=EN-GB> Lamivudine&#8209;refractory patients
and patients harbouring HBV with evidence of resistance to lamivudine
(mutations at rtL180M, rtA181T and/or rtM204I/V) should not be treated with
adefovir dipivoxil monotherapy in order to reduce the risk of resistance to
adefovir.  Adefovir may be used in combination with lamivudine in lamivudine&#8209;refractory
patients and in patients harbouring HBV with mutations at rtL180M and/or
rtM204I/V.  However, for patients harbouring HBV that contains the rtA181T
mutation, consideration should be given to alternative treatment regimens due
to the risk of reduced susceptibility to adefovir (see&nbsp;section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In order to
reduce the risk of resistance in patients receiving adefovir dipivoxil
monotherapy, a modification of treatment should be considered if serum
HBV&nbsp;DNA remains above 1,000&nbsp;copies/ml at or beyond 1&nbsp;year of
treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population:</span></i><span lang=EN-GB> Hepsera is not recommended for use in
children below the age of 18&nbsp;years due to limitations of the available
data on safety and efficacy (see section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepsera tablets
should be taken once daily, orally with or without food.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.3     Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Hypersensitivity to the active substance or to
any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.4     Special warnings and precautions for use</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>General:</span></i><span
lang=EN-GB> Patients should be advised that therapy with adefovir dipivoxil has
not been proven to reduce the risk of transmission of hepatitis&nbsp;B virus to
others and therefore appropriate precautions should still be taken.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Renal
function:</span></i><span lang=EN-GB> Adefovir is excreted renally, by a
combination of glomerular filtration and active tubular secretion.  Treatment
with adefovir dipivoxil may result in renal impairment.  Long&#8209;term
treatment with adefovir dipivoxil may increase the risk of renal impairment.  While
the overall risk of renal impairment in patients with adequate renal function
is low, this is of special importance in patients both at risk of or having
underlying renal dysfunction, and also in patients <span style='layout-grid-mode:
line'>receiving medicinal products that may affect renal function.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='layout-grid-mode:line'>It is recommended that creatinine
clearance is calculated in all patients prior to initiating therapy with
adefovir dipivoxil </span><span lang=EN-GB>and that renal function (creatinine
clearance and serum phosphate) be monitored every four weeks during the first
year and then every three months thereafter.  In patients at risk for renal
impairment, consideration should be given to more frequent monitoring of renal
function.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients who
develop renal insufficiency and have advanced liver disease or cirrhosis,
dosing interval adjustment of adefovir or switch to an alternative therapy for
hepatitis&nbsp;B infection should be considered.  Treatment cessation for
chronic hepatitis&nbsp;B in these patients is not recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Patients with creatinine clearance between 30 and&nbsp;49&nbsp;ml/min:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The dosing
interval of adefovir dipivoxil should be adjusted in these patients (see&nbsp;section&nbsp;4.2).
 In addition, renal function should be closely monitored with a frequency
tailored to the individual patients medical condition.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Patients with creatinine clearance &lt;&nbsp;30&nbsp;ml/min and
dialysis patients:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adefovir
dipivoxil is not recommended in patients with a creatinine clearance of
&lt;&nbsp;30&nbsp;ml/min or on dialysis.  Administration of adefovir dipivoxil
in these patients should only be considered if the potential benefits outweigh
the potential risks.  If treatment with adefovir dipivoxil is considered
essential, then the dosing interval should be adjusted (see&nbsp;section&nbsp;4.2). 
These patients should be closely monitored for possible adverse reactions and
to ensure efficacy is maintained.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Patients receiving medicinal products that may affect renal
function:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adefovir
dipivoxil should not be administered concurrently with tenofovir disoproxil
fumarate (Viread).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Caution is
advised in patients receiving other medicinal products that may affect renal
function or are excreted renally (e.g. cyclosporin and tacrolimus, intravenous
aminoglycosides, amphotericin&nbsp;B, foscarnet, pentamidine, vancomycin, or
medicinal products which are secreted by the same renal transporter, human
Organic Anion Transporter&nbsp;1 (hOAT1), such as cidofovir).  Co&#8209;administration
of 10&nbsp;mg adefovir dipivoxil with medicinal products in these patients may
lead to an increase in serum concentrations of either adefovir or a co&#8209;administered
medicinal product.  The renal function of these patients should be closely
monitored with a frequency tailored to the individual patients medical
condition.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For renal safety
in patients pre&#8209; and post&#8209;transplantation with lamivudine-resistant&nbsp;HBV,
see&nbsp;</span><span lang=EN-GB>section&nbsp;4.8.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic
function:</span></i><span lang=EN-GB> Spontaneous exacerbations in chronic
hepatitis&nbsp;B are relatively common and are characterised by transient
increases in serum ALT.  After initiating antiviral therapy, serum ALT may
increase in some patients as serum HBV&nbsp;DNA levels decline.  In patients
with compensated liver disease, these increases in serum ALT are generally not
accompanied by an increase in serum bilirubin concentrations or hepatic
decompensation (see&nbsp;section&nbsp;4.8).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients with
advanced liver disease or cirrhosis may be at a higher risk for hepatic
decompensation following hepatitis exacerbation which may be fatal.  In these
patients, including patients with decompensated liver disease, treatment
cessation is not recommended and these patients should be monitored closely
during therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>In the event of these patients
developing renal insufficiency, see above <i>Renal function</i>.</span></p>

<p class=MsoEndnoteText><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If treatment
cessation is necessary, patients should be closely monitored for several months
after stopping treatment as exacerbations of hepatitis have occurred after
discontinuation of 10&nbsp;mg adefovir dipivoxil.  These exacerbations occurred
in the absence of HBeAg seroconversion and presented as serum ALT elevations
and increases in serum HBV&nbsp;DNA.  Elevations in serum ALT that occurred in
patients with compensated liver function treated with 10&nbsp;mg adefovir
dipivoxil were not accompanied by clinical and laboratory changes associated
with liver decompensation.  Patients should be closely monitored after stopping
treatment.  Most post&#8209;treatment exacerbations of hepatitis were seen
within 12&nbsp;weeks of discontinuation of 10&nbsp;mg adefovir dipivoxil.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoEndnoteText><i><span lang=EN-GB>Lactic acidosis and severe
hepatomegaly with steatosis:</span></i><span lang=EN-GB> Occurrences of lactic
acidosis (in the absence of hypoxaemia), sometimes fatal, usually associated
with severe hepatomegaly and hepatic steatosis, have been reported with the use
of nucleoside analogues.  As adefovir is structurally related to nucleoside
analogues, this risk cannot be excluded.  Treatment with nucleoside analogues
should be discontinued when rapidly elevating aminotransferase levels,
progressive hepatomegaly or metabolic/lactic acidosis of unknown aetiology
occur.  Benign digestive symptoms, such as nausea, vomiting and abdominal pain,
might be indicative of lactic acidosis development.  Severe cases, sometimes
with fatal outcome, were associated with pancreatitis, liver failure/hepatic
steatosis, renal failure and higher levels of serum lactate.  Caution should be
exercised when prescribing nucleoside analogues to any patient (particularly
obese women) with hepatomegaly, hepatitis or other known risk factors for liver
disease.  These patients should be followed closely.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>To differentiate
between elevations in transaminases due to response to treatment and increases
potentially related to lactic acidosis, physicians should ensure that changes
in ALT are associated with improvements in other laboratory markers of chronic
hepatitis&nbsp;B.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Co&#8209;infection
with hepatitis&nbsp;C or D:</span></i><span lang=EN-GB> There are no data on
the efficacy of adefovir dipivoxil in patients co&#8209;infected with
hepatitis&nbsp;C or hepatitis&nbsp;D.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Co&#8209;infection
with HIV:</span></i><span lang=EN-GB> Limited data are available on the safety
and efficacy of 10&nbsp;mg adefovir dipivoxil in patients with chronic
hepatitis&nbsp;B, co&#8209;infected with HIV.  To date there is no evidence
that daily dosing with 10&nbsp;mg adefovir dipivoxil results in emergence of
adefovir-associated resistance mutations in the HIV&nbsp;reverse
transcriptase.  Nonetheless, there is a potential risk of selection of
HIV&nbsp;strains resistant to adefovir with possible cross&#8209;resistance to
other antiviral medicinal products.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As far as
possible, treatment of hepatitis&nbsp;B by adefovir dipivoxil in an HIV&nbsp;co&#8209;infected
patient should be reserved for patients whose HIV&nbsp;RNA is controlled. 
Treatment with 10&nbsp;mg adefovir dipivoxil has not been shown to be effective
against HIV&nbsp;replication and therefore should not be used to control
HIV&nbsp;infection.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elderly:</span></i><span
lang=EN-GB> The clinical experience in patients &gt;&nbsp;65&nbsp;years of age
is very limited.  Caution should be exercised when prescribing adefovir
dipivoxil to the elderly, keeping in mind the greater frequency of decreased
renal or cardiac function in these patients, and the increase in concomitant
diseases or concomitant use of other medicinal products in the elderly.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Resistance:</span></i><span
lang=EN-GB> Resistance to adefovir dipivoxil (see&nbsp;section&nbsp;5.1) can
result in viral load rebound which may result in exacerbation of
hepatitis&nbsp;B and, in the setting of diminished hepatic function, lead to
liver decompensation and possible fatal outcome.  Virological response should
be closely monitored in patients treated with adefovir dipivoxil, with
HBV&nbsp;DNA measured every 3&nbsp;months.  If viral rebound occurs, resistance
testing should be performed.  In case of emergence of resistance, treatment
should be modified.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepsera contains
lactose monohydrate.  Consequently, patients with rare hereditary problems of
galactose intolerance, the Lapp lactase deficiency, or glucose&#8209;galactose
malabsorption should not take this medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.5     Interaction with other medicinal products and other forms of
interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Interaction
studies have only been performed in adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The potential
for CYP450 mediated interactions involving adefovir with other medicinal
products is low, based on the results of <i>in&nbsp;vitro</i> experiments in
which adefovir did not influence any of the common CYP isoforms known to be
involved in human drug metabolism and based on the known elimination pathway of
adefovir.  A clinical study in liver&#8209;transplant patients has shown that
no pharmacokinetic interaction occurs when adefovir dipivoxil 10&nbsp;mg once
daily is administered concomitantly with tacrolimus, an immunosuppressant which
is predominantly metabolised via the CYP450 system.  A pharmacokinetic
interaction between adefovir and the immunosuppressant, cyclosporin, is also
considered unlikely as cyclosporin shares the same metabolic pathway as
tacrolimus.  Nevertheless, given that tacrolimus and cyclosporin can affect
renal function, close monitoring is recommended when either of these agents is
coadministered with adefovir dipivoxil (see&nbsp;section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Concomitant
administration of 10&nbsp;mg adefovir dipivoxil and 100&nbsp;mg lamivudine did
not alter the pharmacokinetic profile of either medicinal product.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adefovir is
excreted renally, by a combination of glomerular filtration and active tubular
secretion.  Co&#8209;administration of 10&nbsp;mg adefovir dipivoxil with other
medicinal products that are eliminated by tubular secretion or alter tubular
function may increase serum concentrations of either adefovir or the co&#8209;administered
medicinal product (see&nbsp;section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the high
pharmacokinetic variability of pegylated interferon, no definitive conclusion
can be drawn regarding the effect of adefovir and pegylated interferon co&#8209;administration
on the pharmacokinetic profile of either medicinal product.  Even though a
pharmacokinetic interaction is unlikely given the two products are eliminated
via different pathways, caution is recommended if both products are co&#8209;administered.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6     Fertility, pregnancy
and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The use of
adefovir dipivoxil must be accompanied by the use of effective contraception.</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>&nbsp;</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Pregnancy</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are limited
data on the use of adefovir dipivoxil in pregnant women.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Studies in
animals administered adefovir intravenously have shown reproductive toxicity
(see&nbsp;section&nbsp;5.3).  Studies in orally dosed animals do not indicate
teratogenic or foetotoxic effects.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adefovir
dipivoxil is not recommended during pregnancy and in women of childbearing
potential not using contraception.  Adefovir dipivoxil should be used during pregnancy
only if the potential benefit justifies the potential risk to the foetus.</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
data on the effect of adefovir dipivoxil on transmission of HBV from mother to
infant.  Therefore, the standard recommended procedures for immunisation of
infants should be followed to prevent neonatal acquisition of HBV.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Breast&#8209;feeding</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A risk to the
newborns/infants cannot be excluded.  It is recommended that mothers being
treated with adefovir dipivoxil do not breast&#8209;feed their infants.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Fertility</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No human data on
the effect of adefovir dipivoxil on fertility are available.  Animal studies do
not indicate harmful effects of adefovir dipivoxil on male and female
fertility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.7     Effects on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No studies on
the effects on the ability to drive and use machines have been performed. 
However, based on the safety profile and mechanism of action, adefovir
dipivoxil is expected to have no or negligible influence on these abilities.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.8     Undesirable effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
lang=EN-GB>a. Summary of the safety profile</span></i></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
compensated liver disease, the most frequently reported adverse reactions
during 48&nbsp;weeks of adefovir dipivoxil therapy were asthenia (13&nbsp;%),
headache (9&nbsp;%), abdominal pain (9&nbsp;%) and nausea (5&nbsp;%).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In patients with
decompensated liver disease, the most frequently reported adverse reactions
during up to 203&nbsp;weeks of adefovir dipivoxil therapy were increased
creatinine (7&nbsp;%) and asthenia (5&nbsp;%).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
lang=EN-GB>b. Tabulated summary of adverse reactions</span></i></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Assessment of adverse reactions is based on experience from
post-marketing surveillance and from three pivotal clinical studies in patients
with chronic hepatitis&nbsp;B:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>two placebo&#8209;controlled studies in which
522&nbsp;patients with chronic hepatitis&nbsp;B and compensated liver disease
received double-blind treatment with 10&nbsp;mg adefovir dipivoxil (n=294) or
placebo (n=228) for 48&nbsp;weeks.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>an open-label study in which pre&#8209; (n=226)
and post&#8209;liver transplantation patients (n=241) with lamivudine-resistant
HBV were treated with 10&nbsp;mg adefovir dipivoxil once daily, for up to
203&nbsp;weeks (median 51 and 99&nbsp;weeks, respectively).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The adverse
reactions considered at least possibly related to treatment are listed below,
by body system organ class, and frequency (see Table&nbsp;1).  Within each
frequency grouping, undesirable effects are presented in order of decreasing
seriousness.  Frequencies are defined as very common (&#8805;&nbsp;1/10),
common (&#8805;&nbsp;1/100, &lt;&nbsp;1/10) or not known (identified through
post-marketing safety surveillance and the frequency cannot be estimated from
the available data).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><a
name="OLE_LINK7"></a><a name="OLE_LINK8"><b><span lang=EN-GB>Table&nbsp;1:
Tabulated summary of adverse reactions associated with adefovir dipivoxil based
on clinical study and post&#8209;marketing experience</span></b></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='width:100.0%;border-collapse:collapse;border:none'>
 <tr>
  <td width="19%" style='width:19.48%;border:solid windowtext 1.0pt;padding:
  0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Frequency</span></b></p>
  </td>
  <td width="80%" style='width:80.52%;border:solid windowtext 1.0pt;border-left:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB>Adefovir dipivoxil</span></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='color:black'>Nervous system disorders:</span></i></p>
  </td>
 </tr>
 <tr>
  <td width="19%" style='width:19.48%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Common:</span></p>
  </td>
  <td width="80%" style='width:80.52%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Headache</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='color:black'>Gastrointestinal disorders:</span></i></p>
  </td>
 </tr>
 <tr>
  <td width="19%" style='width:19.48%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Common:</span></p>
  </td>
  <td width="80%" style='width:80.52%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Diarrhoea, vomiting,
  abdominal pain, dyspepsia, nausea, flatulence</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" style='width:19.48%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Not known:</span></p>
  </td>
  <td width="80%" style='width:80.52%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Pancreatitis</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='color:black'>Skin and subcutaneous tissue disorders:</span></i></p>
  </td>
 </tr>
 <tr>
  <td width="19%" style='width:19.48%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Common:</span></p>
  </td>
  <td width="80%" style='width:80.52%;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Rash, pruritus</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='color:black'>Musculoskeletal and connective tissue
  disorders:</span></i></p>
  </td>
 </tr>
 <tr>
  <td width="19%" style='width:19.48%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Not known:</span></p>
  </td>
  <td width="80%" valign=top style='width:80.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Osteomalacia (manifested as bone pain and infrequently
  contributing to fractures) and myopathy, both associated with proximal renal
  tubulopathy</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='color:black'>Renal and urinary disorders:</span></i></p>
  </td>
 </tr>
 <tr>
  <td width="19%" style='width:19.48%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Very common:</span></p>
  </td>
  <td width="80%" valign=top style='width:80.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Increases in
  creatinine</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" style='width:19.48%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Common:</span></p>
  </td>
  <td width="80%" valign=top style='width:80.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Renal failure, abnormal renal function, hypophosphatemia</span></p>
  </td>
 </tr>
 <tr>
  <td width="19%" style='width:19.48%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Not known:</span></p>
  </td>
  <td width="80%" valign=top style='width:80.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB>Fanconi syndrome, proximal renal tubulopathy</span></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan=2 style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;background:#E6E6E6;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='color:black'>General disorders and administration site
  conditions:</span></i></p>
  </td>
 </tr>
 <tr>
  <td width="19%" style='width:19.48%;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Very common:</span></p>
  </td>
  <td width="80%" valign=top style='width:80.52%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Asthenia</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
lang=EN-GB>c. Description of selected adverse reactions</span></i></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Exacerbation of hepatitis:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical and
laboratory evidence of exacerbations of hepatitis have occurred after
discontinuation of treatment with 10&nbsp;mg adefovir dipivoxil
(see&nbsp;section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Long&#8209;term safety data in patients with compensated disease:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a long&#8209;term
safety study of 125&nbsp;HBeAg negative patients with compensated liver
disease, the adverse event profile was overall unchanged after a median
exposure of 226&nbsp;weeks.  No clinically significant changes in renal
function were observed.  However, mild to moderate increases in serum
creatinine concentrations, hypophosphatemia and a decrease in carnitine concentrations
were reported in 3&nbsp;%, 4&nbsp;% and 6&nbsp;% of patients, respectively, on
extended treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a long&#8209;term
safety study of 65&nbsp;HBeAg positive patients with compensated liver disease
(after a median exposure of 234&nbsp;weeks), 6&nbsp;patients (9&nbsp;%) had
confirmed increases in serum creatinine of at least 0.5&nbsp;mg/dl from
baseline with 2&nbsp;patients discontinuing from the study due to the elevated
serum creatinine concentration.  Patients with a confirmed increase in
creatinine of &#8805;&nbsp;0.3&nbsp;mg/dl by week&nbsp;48 were at a
statistically significant higher risk of a subsequent confirmed increase in
creatinine of &#8805;&nbsp;0.5&nbsp;mg/dl.  Hypophosphatemia and a decrease in
carnitine concentrations were reported each in 3&nbsp;% of patients on extended
treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Based on
post-marketing data, long&#8209;term treatment with adefovir dipivoxil may lead
to progressive alteration of renal function resulting in renal impairment (see
section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Safety in patients with decompensated disease:</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Renal toxicity
is an important feature of the safety profile of adefovir dipivoxil in patients
with decompensated liver disease.  In clinical studies of wait-listed and
post-liver transplantation patients, four percent (19/467) of patients
discontinued treatment with adefovir dipivoxil due to renal adverse events.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
lang=EN-GB>d. Paediatric population</span></i></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Because of
insufficient data on safety and efficacy, Hepsera should not be used in
children under the age of 18&nbsp;years (see Sections&nbsp;4.2 and 5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Reporting suspected adverse reactions after authorisation of the
medicinal product is important.  It allows continued monitoring of the
benefit/risk balance of the medicinal product.  Healthcare professionals are
asked to report any suspected adverse reactions via <span style='color:black;
background:#D9D9D9'>the national reporting system listed in </span></span><span
lang=EN-GB style='color:black;background:#D9D9D9'><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:black;text-decoration:none'>Appendix&nbsp;V</span></a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.9     Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Administration
of 500&nbsp;mg adefovir dipivoxil daily for 2&nbsp;weeks and 250&nbsp;mg daily
for 12&nbsp;weeks has been associated with the gastrointestinal disorders
listed above and anorexia.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If overdose
occurs, the patient must be monitored for evidence of toxicity, and standard
supportive treatment applied as necessary.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adefovir can be
removed by haemodialysis; the median haemodialysis clearance of adefovir is
104&nbsp;ml/min.  The elimination of adefovir by peritoneal dialysis has not
been studied.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.       PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1     Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Pharmacotherapeutic
group:</span></i><span lang=EN-GB> Nucleoside and nucleotide reverse
transcriptase inhibitors, ATC code: J05AF08.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><u><span lang=EN-GB>Mechanism
of action and pharmacodynamic effects:</span></u></i><span lang=EN-GB> </span><span
lang=EN-GB>Adefovir dipivoxil is an oral prodrug of adefovir, an acyclic
nucleotide phosphonate analogue of adenosine monophosphate, which is actively
transported into mammalian cells where it is converted by host enzymes to
adefovir diphosphate.  Adefovir diphosphate inhibits viral polymerases by
competing for direct binding with the natural substrate (deoxyadenosine
triphosphate) and, after incorporation into viral DNA, causes DNA chain
termination.  Adefovir diphosphate selectively inhibits HBV&nbsp;DNA
polymerases at concentrations 12&#8209;, 700&#8209;, and 10&#8209;fold lower
than those needed to inhibit human DNA polymerases &#945;, &#946;, and &#947;,
respectively.  Adefovir diphosphate has an intracellular half&#8209;life of 12
to 36&nbsp;hours in activated and resting lymphocytes.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adefovir is
active against hepadnaviruses <i>in&nbsp;vitro</i>, including all common forms
of lamivudine-resistant HBV (rtL180M, rtM204I, rtM204V, rtL180M/rtM204V),
famciclovir-associated mutations (rtV173L, rtP177L, rtL180M, rtT184S or
rtV207I) and hepatitis&nbsp;B immunoglobulin escape mutations (rtT128N and
rtW153Q), and in <i>in&nbsp;vivo</i> animal models of hepadnavirus replication.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Clinical efficacy and safety:</span></u></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The demonstration of the benefit of adefovir dipivoxil is based on
histological, virological, biochemical, and serological responses in adults
with:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>HBeAg positive and HBeAg negative chronic
hepatitis&nbsp;B with compensated liver disease.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>lamivudine-resistant HBV with either compensated
or decompensated liver disease, including patients pre&#8209; and post&#8209;liver
transplantation or co&#8209;infected with HIV.  In the majority of these
studies adefovir dipivoxil 10&nbsp;mg was added to ongoing lamivudine treatment
in patients failing lamivudine therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In these
clinical studies patients had active viral replication (HBV&nbsp;DNA &#8805;&nbsp;100,000&nbsp;copies/ml)
and elevated ALT levels (&#8805;&nbsp;1.2&nbsp;x Upper Limit of Normal (ULN)).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Experience in
patients with compensated liver disease:</span></i><span lang=EN-GB> In two
placebo-controlled studies (total n=522) in HBeAg positive or in HBeAg negative
chronic hepatitis&nbsp;B patients with compensated liver disease, significantly
more patients (p&nbsp;&lt;&nbsp;0.001) in the 10&nbsp;mg adefovir dipivoxil
groups (53 and 64&nbsp;%, respectively) had histological improvement from
baseline at week&nbsp;48 than in the placebo groups (25 and 33&nbsp;%). 
Improvement was defined as a reduction from baseline of two points or more in
the Knodell necro-inflammatory score with no concurrent worsening in the
Knodell fibrosis score.  Histological improvement was seen regardless of
baseline demographic and hepatitis&nbsp;B characteristics, including prior
interferon&#8209;alpha therapy.  High baseline ALT levels
(&#8805;&nbsp;2&nbsp;x&nbsp;ULN) and Knodell Histology Activity Index (HAI)
scores (&#8805;&nbsp;10) and low HBV&nbsp;DNA (&lt;&nbsp;7.6&nbsp;log<sub>10</sub>&nbsp;copies/ml)
were associated with greater histological improvement.  Blinded, ranked assessments
of both necro-inflammatory activity and fibrosis at baseline and week&nbsp;48,
demonstrated that patients treated with 10&nbsp;mg adefovir dipivoxil had
improved necro-inflammatory and fibrosis scores relative to placebo-treated
patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Assessment of
the change in fibrosis after 48&nbsp;weeks treatment using the Knodell scores
confirms that patients treated with adefovir dipivoxil 10&nbsp;mg had more
regression and less progression of fibrosis than patients treated with placebo.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the two
studies mentioned above, treatment with 10&nbsp;mg adefovir dipivoxil was
associated with significant reductions in serum HBV&nbsp;DNA (3.52 and
3.91&nbsp;log<sub>10</sub>&nbsp;copies/ml, respectively, <i>versus</i> 0.55 and
1.35&nbsp;log<sub>10</sub>&nbsp;copies/ml), increased proportion of patients
with normalisation of ALT (48 and 72&nbsp;% <i>versus</i> 16 and 29&nbsp;%) or
increased proportion of patients with serum HBV&nbsp;DNA below the limits of
quantification (&lt;&nbsp;400&nbsp;copies/ml Roche Amplicor Monitor PCR assay)
(21 and 51&nbsp;% <i>versus</i> 0&nbsp;%) when compared with placebo.  In the
study in HBeAg positive patients, HBeAg seroconversion (12&nbsp;%) and HBeAg
loss (24&nbsp;%) was observed significantly more frequently in patients
receiving 10&nbsp;mg adefovir dipivoxil than in patients receiving placebo
(6&nbsp;% and 11&nbsp;%, respectively) after 48&nbsp;weeks of treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the HBeAg&nbsp;positive
study, treatment beyond 48&nbsp;weeks resulted in further reductions in serum
HBV&nbsp;DNA levels and increases in the proportion of patients with ALT
normalisation, HBeAg loss and seroconversion.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the
HBeAg&nbsp;negative study patients on adefovir dipivoxil (0&#8209;48&nbsp;weeks)
were re-randomised in a blinded-manner to continue on adefovir dipivoxil or
receive placebo for an additional 48&nbsp;weeks.  At week&nbsp;96, patients
continuing on adefovir dipivoxil 10&nbsp;mg had sustained suppression of serum
HBV&nbsp;with maintenance of the reduction seen at week&nbsp;48.  In over two
thirds of patients suppression of serum HBV&nbsp;DNA was associated with
normalisation of ALT levels.  In most patients who stopped treatment with
adefovir dipivoxil, serum HBV&nbsp;DNA and ALT levels returned towards
baseline.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with
adefovir dipivoxil resulted in improvement in the liver fibrosis from baseline
to 96&nbsp;weeks therapy when analysed using the Ishak score (median change: &#916;=&nbsp;&#8209;1). 
No differences in the median fibrosis score were seen between groups using the
Knodell fibrosis score.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients who
completed the first 96&nbsp;weeks of the HBeAg&nbsp;negative study and received
adefovir dipivoxil treatment during weeks&nbsp;49 to 96, were offered the
opportunity to receive open-label treatment with adefovir dipivoxil from study
week&nbsp;97 through to week&nbsp;240.  Serum HBV&nbsp;DNA levels remained
undetectable and ALT levels normalised in approximately two thirds of patients
following treatment with adefovir dipivoxil for up to 240&nbsp;weeks. 
Clinically and statistically significant improvement in fibrosis was seen in
the changes in Ishak scores from the start of adefovir dipivoxil treatment to
the end of the study (week&nbsp;240) (median change: &#916;=&nbsp;&#8209;1). 
By the end of the study, 7 of 12&nbsp;patients (58&nbsp;%) with bridging
fibrosis or cirrhosis at baseline, had an improved Ishak fibrosis score of
&#8805;&nbsp;2&nbsp;points.  Five patients achieved and maintained HBsAg
seroconversion (HBsAg&nbsp;negative/HBsAb&nbsp;positive).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Experience in
patients pre&#8209; and post&#8209;liver transplantation with lamivudine&#8209;resistant
HBV:</span></i><span lang=EN-GB> In a clinical study in 394 chronic
hepatitis&nbsp;B patients with lamivudine-resistant HBV<span style='layout-grid-mode:
line'> </span>(pre&#8209;liver transplantation (n=186) and post&#8209;liver
transplantation (n=208)), treatment with 10&nbsp;mg adefovir dipivoxil resulted
in a median reduction in serum HBV&nbsp;DNA of 4.1 and 4.2&nbsp;log<sub>10</sub>&nbsp;copies/ml,
respectively, at week&nbsp;48.  In the pre&#8209;liver transplantation and post&#8209;liver
transplantation cohorts 77 of 109 (71&nbsp;%) patients and 64 of 159
(40&nbsp;%) patients, respectively, achieved undetectable HBV&nbsp;DNA levels
at week&nbsp;48 (&lt;&nbsp;1,000&nbsp;copies/ml Roche Amplicor Monitor PCR
assay).  Treatment with 10&nbsp;mg adefovir dipivoxil showed similar efficacy
regardless of the patterns of lamivudine-resistant HBV&nbsp;DNA polymerase
mutations at baseline.  Improvements or stabilisation were seen in
Child-Pugh-Turcotte score.  Normalisation of ALT, albumin, bilirubin and
prothrombin time was seen at week&nbsp;48 in 51&#8209;85&nbsp;% of the
patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In the pre&#8209;liver
transplantation cohort, 25 of 33 (76&nbsp;%) patients achieved undetectable
HBV&nbsp;DNA levels and 84&nbsp;% of patients had ALT normalisation at
96&nbsp;weeks.  In the post&#8209;liver transplantation cohort, 61 of 94
(65&nbsp;%) and 35 of 45 (78&nbsp;%) of patients achieved undetectable
HBV&nbsp;DNA levels at 96&nbsp;and 144&nbsp;weeks, respectively, and 70&nbsp;%
and 58&nbsp;% of patients had ALT normalisation at these study visits.  The
clinical significance of these findings as they relate to histological
improvement is not known.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Experience in
patients with compensated liver disease and lamivudine&#8209;resistant HBV:</span></i><span
lang=EN-GB> In a double&#8209;blind comparative study in chronic
hepatitis&nbsp;B <span style='layout-grid-mode:line'>patients with </span>lamivudine&#8209;resistant
HBV<span style='layout-grid-mode:line'> </span>(n=58),<span style='layout-grid-mode:
line'> there was no </span>median reduction in HBV&nbsp;DNA from baseline<span
style='layout-grid-mode:line'> after </span>48&nbsp;weeks of treatment with
lamivudine.  Forty-eight weeks of treatment with adefovir dipivoxil 10&nbsp;mg
alone or in combination with lamivudine resulted in a similar significant
decrease in median serum HBV&nbsp;DNA levels from baseline (4.04&nbsp;<span
style='layout-grid-mode:line'>log<sub>10</sub>&nbsp;copies/ml and 3.59&nbsp;log<sub>10</sub>&nbsp;copies/ml,
respectively).  The clinical significance of these observed changes in
HBV&nbsp;DNA has </span>not been established.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Experience in
patients with decompensated liver disease and lamivudine&#8209;resistant HBV:</span></i><span
lang=EN-GB> In 40 HBeAg positive or HBeAg negative patients with
lamivudine-resistant HBV and decompensated liver disease receiving treatment
with 100&nbsp;mg lamivudine, addition of 10&nbsp;mg adefovir dipivoxil
treatment for 52&nbsp;weeks resulted in a median reduction in HBV&nbsp;DNA of
4.6&nbsp;log<sub>10</sub>&nbsp;copies/ml.  Improvement in liver function was
also seen after one year of therapy.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Experience in
patients with HIV co&#8209;infection and lamivudine&#8209;resistant HBV:</span></i><span
lang=EN-GB> In an open-label investigator study in 35 chronic hepatitis&nbsp;B
patients with lamivudine-resistant HBV and co&#8209;infected with HIV,
continued treatment with 10&nbsp;mg adefovir dipivoxil resulted in progressive
reductions in serum HBV&nbsp;DNA levels and ALT levels throughout the course of
treatment up to 144&nbsp;weeks.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a second open&#8209;label,
one&#8209;arm study, 10&nbsp;mg adefovir dipivoxil and pegylated interferon
alpha&#8209;2a were added to ongoing lamivudine therapy in 18 HIV/HBV co&#8209;infected
patients with lamivudine&#8209;resistant HBV.  Patients were all HBeAg&nbsp;positive
and had median CD4 cell count of 441&nbsp;cells/mm<sup>3</sup> (no patient had
CD4 count &lt;&nbsp;200&nbsp;cells/mm<sup>3</sup>).  During therapy, serum HBV&nbsp;DNA
levels were significantly lower compared to baseline for up to 48&nbsp;weeks of
treatment while ALT levels declined progressively from week&nbsp;12.  However,
on&#8209;treatment HBV&nbsp;DNA response was not maintained off&#8209;therapy
since all the patients had a rebound in HBV&nbsp;DNA after adefovir dipivoxil
and pegylated interferon alpha&#8209;2a discontinuation.  No patients became
HBsAg&#8209; or HBeAg&#8209;negative during the study.  Due to the small sample
size and the study design, in particular the lack of treatment arms with
pegylated interferon alpha&#8209;2a monotherapy and with adefovir monotherapy, it
is not possible to draw formal conclusions on the best therapeutic management
of HIV co&#8209;infected patients with lamivudine&#8209;resistant HBV.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:8.1pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Clinical resistance in patients receiving adefovir
dipivoxil as monotherapy and in combination with lamivudine:</span></i><span
lang=EN-GB> In several clinical studies (HBeAg&nbsp;positive,
HBeAg&nbsp;negative, pre&#8209; and post-liver transplantation with
lamivudine-resistant HBV and lamivudine-resistant HBV co&#8209;infected with
HIV patients), genotypic analyses were conducted on HBV isolates from 379 of a
total of 629&nbsp;patients, treated with adefovir dipivoxil for 48&nbsp;weeks. 
No HBV&nbsp;DNA polymerase mutations associated with resistance to adefovir
were identified when patients were genotyped at baseline and at week&nbsp;48. 
After 96, 144, 192 and 240&nbsp;weeks of treatment with adefovir dipivoxil,
resistance surveillance was performed for 293, 221, 116 and 64&nbsp;patients,
respectively.  Two novel conserved site mutations were identified in the HBV
polymerase gene (rtN236T and rtA181V), which conferred clinical resistance to
adefovir dipivoxil.  The cumulative probabilities of developing these
adefovir-associated resistance mutations in all patients treated with adefovir
dipivoxil were 0&nbsp;% at 48&nbsp;weeks and approximately 2&nbsp;%, 7&nbsp;%, 14&nbsp;%
and 25&nbsp;% after 96, 144, 192 and 240&nbsp;weeks, respectively.</span></p>

<p class=MsoNormal style='margin-right:8.1pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:8.1pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Clinical resistance in monotherapy studies in
nucleoside naïve patients:</span></i><span lang=EN-GB> In patients receiving
adefovir dipivoxil monotherapy (HBeAg&nbsp;negative study) the cumulative
probability of developing adefovir&#8209;associated resistance mutations was
0&nbsp;%, 3&nbsp;%, 11&nbsp;%, 18&nbsp;% and 29&nbsp;% at 48, 96, 144, 192 and
240&nbsp;weeks respectively.  In addition, the long&#8209;term (4 to
5&nbsp;years) development of resistance to adefovir dipivoxil was significantly
lower in patients who had serum HBV&nbsp;DNA below the limit of quantification
(&lt;&nbsp;1,000&nbsp;copies/ml) at week&nbsp;48 as compared to patients with
serum HBV&nbsp;DNA above 1,000&nbsp;copies/ml at week&nbsp;48.  In HBeAg&nbsp;positive
patients, the incidence of adefovir-associated resistance mutations was
3&nbsp;% (2/65), 17&nbsp;% (11/65) and 20&nbsp;% (13/65) after a median
duration exposure of 135, 189 and 235&nbsp;weeks respectively.</span></p>

<p class=MsoNormal style='margin-right:8.1pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:8.1pt;line-height:normal;text-autospace:
none'><i><span lang=EN-GB>Clinical resistance in studies where adefovir
dipivoxil was added to ongoing lamivudine in patients with
lamivudine-resistance:</span></i><span lang=EN-GB> In an open-label study of
pre&#8209; and post&#8209;liver transplantation patients with clinical evidence
of lamivudine-resistant HBV, no adefovir-associated resistance mutations were
observed at week&nbsp;48.  With up to 3&nbsp;years of exposure, no patients
receiving both adefovir dipivoxil and lamivudine developed resistance to
adefovir dipivoxil.  However, 4&nbsp;patients who discontinued lamivudine
treatment developed the rtN236T mutation while receiving adefovir dipivoxil
monotherapy and all experienced serum HBV rebound.</span></p>

<p class=MsoNormal style='margin-right:8.1pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:8.1pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>The currently available data both <i>in&nbsp;vitro</i>
and in patients suggest that HBV expressing the adefovir-associated resistance
mutation rtN236T is susceptible to lamivudine.  Preliminary clinical data
suggest the adefovir-associated resistance mutation rtA181V may confer a
reduced susceptibility to lamivudine, and the lamivudine&#8209;associated
mutation rtA181T may confer a reduced susceptibility to adefovir dipivoxil.</span></p>

<p class=MsoNormal style='margin-right:8.1pt;line-height:normal;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>Paediatric population:</span></u></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The efficacy and
safety of a daily dose of 0.25&nbsp;mg/kg to 10&nbsp;mg adefovir dipivoxil in
children (aged from 2 to&nbsp;&lt;&nbsp;18&nbsp;years) were examined in a
double&#8209;blind, randomised, placebo&#8209;controlled study in 173
paediatric patients (115 on adefovir dipivoxil, 58 on placebo) who had
HBeAg&nbsp;positive chronic hepatitis&nbsp;B, serum ALT levels
&#8805;&nbsp;1.5&nbsp;x upper limit of normal (ULN) and compensated liver
disease.  At week&nbsp;48, in children aged 2 to 11&nbsp;years old, no
statistically significant difference was observed in the proportions of
patients that achieved the primary endpoint of serum HBV<span style='color:
black;background:white'>&nbsp;</span>DNA<span style='color:black;background:
white'> </span>&lt;&nbsp;1,000&nbsp;copies/ml and normal ALT levels between the
placebo arm and the adefovir dipivoxil arm.  In the adolescent population
(n=83) (aged from 12 to &lt;&nbsp;18&nbsp;years), significantly more patients
treated with adefovir dipivoxil achieved the primary efficacy endpoint and
obtained significant reductions in serum HBV<span style='color:black;
background:white'>&nbsp;</span>DNA<span style='color:black;background:white'> </span>(23&nbsp;%)
compared to placebo&#8209;treated patients (0&nbsp;%).  However, the
proportions of subjects who achieved HBeAg seroconversion at week&nbsp;48 were
similar (11&nbsp;%) between the placebo arm and the adefovir dipivoxil
10&nbsp;mg arm in adolescent patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Overall, the
safety profile of adefovir dipivoxil in children was consistent with the known
safety profile in adult patients.  However, a signal towards a higher rate of
decreased appetite and/or food intake was observed in the adefovir arm as
compared to the placebo arm.  At week&nbsp;48 and 96, mean changes from
baseline in weight and BMI&nbsp;Z&nbsp;scores tended to decrease in adefovir
dipivoxil&#8209;treated patients.   At week&nbsp;48, all placebo-treated
subjects who did not exhibit HBeAg or HBsAg seroconversion, plus all adefovir
dipivoxil&#8209;treated subjects, were offered the opportunity to receive
open-label adefovir dipivoxil from study week&nbsp;49 through to week&nbsp;240. 
A high rate (30%) of hepatic flares was reported following discontinuation of
adefovir dipivoxil during the 3&nbsp;years open&#8209;label phase of the
study.  Furthermore, for the few patients who remained on drug at week&nbsp;240
(n=12) BMI&nbsp;Z&nbsp;score was lower than typical for their age and gender. 
Very few patients developed adefovir-associated mutations up to 5&nbsp;years;
however, the number of patients who remained on drugs above week 96&nbsp;was
limited.  Due to their limitations, the clinical data available do not allow to
draw definitive conclusions on the benefit/risk ratio of the adefovir treatment
in children with chronic hepatitis&nbsp;B (see section&nbsp;4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.2     Pharmacokinetic properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adefovir
dipivoxil is a dipivaloyloxymethyl ester prodrug of the active substance
adefovir, an acyclic nucleotide analogue which is actively transported into
cells where it is converted by host enzymes to adefovir diphosphate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Absorption:</span></i><span
lang=EN-GB> The oral bioavailability of adefovir from 10&nbsp;mg adefovir
dipivoxil is 59&nbsp;%.  Following oral administration of a single dose of
10&nbsp;mg adefovir dipivoxil to chronic hepatitis&nbsp;B patients, the median
(range) peak serum concentration (C<sub>max</sub>) was achieved after
1.75&nbsp;h (0.58&#8209;4.0&nbsp;h).  Median C<sub>max</sub> and AUC<sub>0&#8209;&#8734;</sub>
values were 16.70&nbsp;(9.66&#8209;30.56)&nbsp;ng/ml and 204.40&nbsp;(109.75&#8209;356.05)&nbsp;ng<b>·</b>h/ml,
respectively.  Systemic exposure to adefovir was not affected when 10&nbsp;mg
adefovir dipivoxil was taken with a high fat meal.  The t<sub>max</sub> was
delayed by two hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Distribution:</span></i><span
lang=EN-GB> Preclinical studies show that after oral administration of adefovir
dipivoxil, adefovir is distributed to most tissues with the highest
concentrations occurring in kidney, liver and intestinal tissues.  <i>In&nbsp;vitro</i>
binding of adefovir to human plasma or human serum proteins is &#8804;&nbsp;4&nbsp;%,
over the adefovir concentration range of 0.1 to 25&nbsp;&#956;g/ml.  The volume
of distribution at steady&#8209;state following intravenous administration of
1.0 or 3.0&nbsp;mg/kg/day is 392±75 and 352±9&nbsp;ml/kg, respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Biotransformation:</span></i><span
lang=EN-GB> Following oral administration, adefovir dipivoxil is rapidly
converted to adefovir.  At concentrations substantially higher (&gt;&nbsp;4,000&#8209;fold)
than those observed <i>in&nbsp;vivo</i>, adefovir did not inhibit any of the
following human CYP450 isoforms, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP3A4.  Based
on the results of these <i>in&nbsp;vitro</i> experiments and the known
elimination pathway of adefovir, the potential for CYP450 mediated interactions
involving adefovir with other medicinal products is low.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Elimination:</span></i><span
lang=EN-GB> Adefovir is excreted renally by a combination of glomerular
filtration and active tubular secretion.  The median (min&#8209;max) renal
clearance of adefovir in subjects with normal renal function (Cl<sub>cr</sub>&nbsp;&gt;&nbsp;80&nbsp;ml/min)
is 211&#8194;ml/min (172&#8209;316&nbsp;ml/min), approximately twice calculated
creatinine clearance (Cockroft&#8209;Gault method).<u>  </u>After repeated
administration of 10&nbsp;mg adefovir dipivoxil, 45&nbsp;% of the dose is
recovered as adefovir in the urine over 24&nbsp;hours.  Plasma adefovir
concentrations declined in a biexponential manner with a median terminal
elimination half&#8209;life of 7.22&nbsp;h (4.72&#8209;10.70&nbsp;h).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Linearity/non&#8209;linearity:</span></i><span
lang=EN-GB> The pharmacokinetics of adefovir are proportional to dose when
given as adefovir dipivoxil over the dose range of 10 to 60&nbsp;mg.  Repeated
dosing of adefovir dipivoxil 10&nbsp;mg daily did not influence the
pharmacokinetics of adefovir.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Gender, age
and ethnicity:</span></i><span lang=EN-GB> The pharmacokinetics of adefovir
were similar in male and female patients.  Pharmacokinetic studies have not
been conducted in the elderly.  Pharmacokinetic studies were principally
conducted in Caucasian patients.  The available data do not appear to indicate
any difference in pharmacokinetics with regard to race.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment:</span></i><span lang=EN-GB> The mean (± SD)
pharmacokinetic parameters of adefovir following administration of a single
dose of 10&nbsp;mg adefovir dipivoxil to patients with varying degrees of renal
impairment are described in the table below:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=639
 style='margin-left:.9pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid;height:7.5pt'>
  <td width=157 valign=top style='width:117.9pt;border:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><u><span lang=EN-GB><span
   style='text-decoration:none'>&nbsp;</span></span></u></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>Renal Function
  Group</span></b></p>
  </td>
  <td width=215 valign=top style='width:161.1pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>Unimpaired</span></b></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>Mild</span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>Moderate</span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border:solid black 1.0pt;
  border-left:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>Severe</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.5pt'>
  <td width=157 valign=top style='width:117.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:
  avoid'><b><span lang=EN-GB>Baseline Creatinine Clearance (ml/min)</span></b></p>
  </td>
  <td width=215 valign=top style='width:161.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>&gt;&nbsp;80</span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>(n=7)</span></b></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>50&#8209;80</span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>(n=8)</span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>30&#8209;49</span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>(n=7)</span></b></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>10&#8209;29</span></b></p>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><b><span lang=EN-GB>(n=10)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.5pt'>
  <td width=157 valign=top style='width:117.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>C<sub>max</sub> (ng/ml)</span></p>
  </td>
  <td width=215 valign=top style='width:161.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>17.8±3.2</span></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:
  line'>22.4±4.0</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:
  line'>28.5±8.6</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:
  line'>51.6±10.3</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.5pt'>
  <td width=157 valign=top style='width:117.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>AUC<sub>0&#8209;&#8734;</sub> (ng<b>·</b>h/ml)</span></p>
  </td>
  <td width=215 valign=top style='width:161.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:
  line'>201±40.8</span></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>266±55.7</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:
  line'>455±176</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:
  line'>1240±629</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.5pt'>
  <td width=157 valign=top style='width:117.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal;page-break-after:
  avoid'><span lang=EN-GB>CL/F (ml/min)</span></p>
  </td>
  <td width=215 valign=top style='width:161.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB>469±99.0</span></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:
  line'>356±85.6</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:
  line'>237±118</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal;page-break-after:avoid'><span lang=EN-GB style='layout-grid-mode:
  line'>91.7±51.3</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.5pt'>
  <td width=157 valign=top style='width:117.9pt;border:solid black 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal style='margin-top:3.0pt;margin-right:-.1pt;margin-bottom:
  0in;margin-left:0in;margin-bottom:.0001pt;line-height:normal'><span
  lang=EN-GB>CL<sub>renal</sub> (ml/min)</span></p>
  </td>
  <td width=215 valign=top style='width:161.1pt;border-top:none;border-left:
  none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal'><span lang=EN-GB style='layout-grid-mode:line'>231±48.9</span></p>
  </td>
  <td width=97 valign=top style='width:72.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal'><span lang=EN-GB style='layout-grid-mode:line'>148±39.3</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal'><span lang=EN-GB style='layout-grid-mode:line'>83.9±27.5</span></p>
  </td>
  <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:7.5pt'>
  <p class=MsoNormal align=center style='margin-top:3.0pt;margin-right:-.1pt;
  margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:center;
  line-height:normal'><span lang=EN-GB style='layout-grid-mode:line'>37.0±18.4</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>A four-hour
period of haemodialysis removed approximately 35&nbsp;% of the adefovir dose. 
The effect of peritoneal dialysis on adefovir removal has not been evaluated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is
recommended that the dosing interval of 10&nbsp;mg adefovir dipivoxil is
modified in patients with creatinine clearance between 30 and&nbsp;49&nbsp;ml/min.
 Adefovir dipivoxil is not recommended in patients with creatinine clearance of
&lt;&nbsp;30&nbsp;ml/min or in patients on dialysis (see&nbsp;section&nbsp;4.2
and 4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Hepatic
impairment:</span></i><span lang=EN-GB> Pharmacokinetic properties were similar
in patients with moderate and severe hepatic impairment compared to healthy
volunteers (see&nbsp;section&nbsp;4.2).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>Paediatric
population: </span></i><span lang=EN-GB>The pharmacokinetics of adefovir
dipivoxil were studied in an efficacy and safety study of a daily dose of
0.25&nbsp;mg/kg to 10&nbsp;mg adefovir dipivoxil in children (aged 2 to
&lt;&nbsp;18&nbsp;years).  Pharmacokinetic analysis revealed that adefovir
exposure was comparable among 3 age groups, 2 to 6&nbsp;years (0.3&nbsp;mg/kg),
7 to 11&nbsp;years (0.25&nbsp;mg/kg) and 12 to 17&nbsp;years (10&nbsp;mg) and
all age groups achieved adefovir exposure in the target range (for efficacy
results see&nbsp;section&nbsp;5.1), which was based on adefovir plasma
concentrations in adult patients with chronic hepatitis&nbsp;B with established
safety and efficacy profiles.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3     Preclinical safety
data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The primary dose&#8209;limiting
toxic effect associated with administration of adefovir dipivoxil in animals
(mice, rats and monkeys) was renal tubular nephropathy characterised by
histological alterations and/or increases in blood urea nitrogen and serum
creatinine.  Nephrotoxicity was observed in animals at systemic exposures at
least 3&#8209;10&nbsp;times higher than those achieved in humans at the
recommended therapeutic dose of 10&nbsp;mg/day.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No effects on
male or female fertility, or reproductive performance, occurred in rats and
there was no embryotoxicity or teratogenicity in rats or rabbits administered
adefovir dipivoxil orally.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When adefovir
was administered intravenously to pregnant rats at doses associated with
notable maternal toxicity (systemic exposure 38&nbsp;times that achieved in
humans at the therapeutic dose) embryotoxicity and an increased incidence of
foetal malformations (anasarca, depressed eye bulge, umbilical hernia and
kinked tail) were observed.  No adverse effects on development were seen at
systemic exposures approximately 12&nbsp;times that achieved in humans at the
therapeutic dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adefovir
dipivoxil was mutagenic in the <i>in&nbsp;vitro</i> mouse lymphoma cell assay
(with or without metabolic activation), but was not clastogenic in the <i>in&nbsp;vivo</i>
mouse micronucleus assay.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adefovir was not
mutagenic in microbial mutagenicity assays involving <i>Salmonella typhimurium</i>
(Ames) and <i>Escherichia coli</i> in the presence and absence of metabolic
activation.  Adefovir induced chromosomal aberrations in the <i>in&nbsp;vitro</i>
human peripheral blood lymphocyte assay without metabolic activation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In long&#8209;term
carcinogenicity studies in rats and mice with adefovir dipivoxil, no
treatment-related increase in tumour incidence was found in mice or rats
(systemic exposures approximately 10 and 4&nbsp;times those achieved in humans
at the therapeutic dose of 10&nbsp;mg/day, respectively).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.       PHARMACEUTICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1     List of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Pregelatinised starch</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Croscarmellose sodium</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Lactose monohydrate</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talc</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Magnesium
stearate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2     Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3     Shelf life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>2&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4     Special precautions
for storage</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30ºC.  Store in the original package in order to protect from moisture.  Keep
the bottle tightly closed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.5     Nature and contents
of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepsera is
supplied in high-density polyethylene (HDPE) bottles with a child&#8209;resistant
closure.  Each bottle contains 30&nbsp;tablets, silica gel desiccant and fibre
packing material.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
pack sizes are available: outer cartons containing 1&nbsp;bottle of
30&nbsp;tablets and outer cartons containing 90&nbsp;(3&nbsp;bottles of
30)&nbsp;tablets.  Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.6     Special precautions
for disposal</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused medicinal
product or waste material should be disposed of in accordance with local
requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.       MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead Sciences
Ireland UC</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Carrigtohill</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>County Cork, T45
DP77</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.       MARKETING AUTHORISATION
NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/03/251/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/03/251/002</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9.       DATE OF FIRST
AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Date of first authorisation: 06 March 2003</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of latest
renewal: 06 March 2008</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10.     DATE OF REVISION OF
THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>{MM/YYYY}</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed information
on this medicinal product is available on the website of the European Medicines
Agency http://www.ema.europa.eu</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:70.8pt;margin-bottom:
0in;margin-left:85.05pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>A.      MANUFACTURER(S) RESPONSIBLE FOR BATCH
RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>B.      CONDITIONS OR RESTRICTIONS REGARDING SUPPLY
AND USE</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>C.      OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:85.05pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>D.      CONDITIONS OR RESTRICTIONS WITH REGARD TO
THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:77.9pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB style='page-break-after:avoid'><span lang=EN-GB>A.      MANUFACTURER(S)
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Name and address of the manufacturer(s) responsible for batch
release</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Gilead Sciences Ireland UC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>IDA Business &amp; Technology Park</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Carrigtohill Co. Cork</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB style='page-break-after:avoid'><span lang=EN-GB>B.      CONDITIONS
OR RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (see Annex&nbsp;I: Summary
of Product Characteristics, section&nbsp;4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB style='page-break-after:avoid'><span lang=EN-GB>C.      OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic Safety Update Reports</span></b></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>The marketing authorisation holder shall submit periodic safety
update reports for this product in accordance with the requirements set out in
the list of Union reference dates (EURD list) provided for under Article
107c(7) of Directive 2001/83</span><span lang=EN-GB>/EC</span><span lang=EN-GB>
and published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleB style='page-break-after:avoid'><span lang=EN-GB>D.      CONDITIONS
OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT</span></p>

<p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
page-break-after:avoid;background:white'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:.5in;margin-bottom:.0001pt;text-indent:-.5in;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
page-break-after:avoid;background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>The MAH shall perform
the required pharmacovigilance activities and interventions detailed in the
agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any
agreed subsequent updates of the RMP.</span></p>

<p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.05pt;margin-bottom:
0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
background:white'><span lang=EN-GB style='color:black'>If the dates for
submission of a PSUR and the update of a RMP coincide, they can be submitted at
the same time.</span></p>

<p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=SPCList style='line-height:normal;page-break-after:avoid;background:
white'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB style='color:black'>Obligation to conduct
post-authorisation measures</span></b></p>

<p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
page-break-after:avoid;background:white'><span lang=EN-GB>&nbsp;</span></p>

<p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
page-break-after:avoid;background:white'><span lang=EN-GB style='color:black'>The
MAH shall complete, within the stated timeframe, the following measures:</span></p>

<p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
page-break-after:avoid;background:white'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=518 valign=top style='width:388.15pt;border:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
  page-break-after:avoid;background:white'><b><span lang=EN-GB
  style='color:black'>Description</span></b></p>
  </td>
  <td width=102 valign=top style='width:76.2pt;border:solid windowtext 1.0pt;
  border-left:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
  page-break-after:avoid;background:white'><b><span lang=EN-GB
  style='color:black'>Due date</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=518 valign=top style='width:388.15pt;border:solid windowtext 1.0pt;
  border-top:none;background:white;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='color:black'>The MAH commits to ensure continuous assessment of
  cross-resistance of adefovir to established and new nucleos(t)ide analogues,
  and provide reviews of these assessments as new data becomes available. The
  role of adefovir and add-on lamivudine+adefovir in HBV therapy strategy
  should be regularly discussed in the light of emerging data.</span></p>
  </td>
  <td width=102 valign=top style='width:76.2pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  background:white;padding:0in 5.4pt 1.4pt 5.4pt'>
  <p class=SPCList style='margin-left:0in;text-indent:0in;line-height:normal;
  page-break-after:avoid;background:white'><span lang=EN-GB style='color:black'>As
  data becomes available</span></p>
  </td>
 </tr>
</table>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal;background:
white'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
color:black'><br clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;background:white'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE
PACKAGING</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;border:none;padding:0in'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>CARTON AND BOTTLE LABELLING</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.       NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Hepsera 10&nbsp;mg tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Adefovir
dipivoxil</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.       STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each tablet
contains 10&nbsp;mg adefovir dipivoxil.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.       LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Contains lactose
monohydrate, see package leaflet for further information.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.       PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>30&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>90 (3&nbsp;bottles of 30)&nbsp;tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.       METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Read the package
leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.       SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.       OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.       EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.       SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30ºC.  Store in the original package in order to protect from moisture. 
Keep the bottle tightly closed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.     SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.     NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Gilead Sciences Ireland UC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Carrigtohill</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>County Cork, T45 DP77</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.     MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>EU/1/03/251/001 <span style='color:black;background:#D9D9D9'>30&nbsp;tablets</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>EU/1/03/251/002 90 (3&nbsp;bottles of 30)&nbsp;tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.     BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.     GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.     INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.     INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Hepsera</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#D9D9D9'>[</span><span lang=EN-GB
style='color:black;background:#D9D9D9'>outer packaging only</span><span
lang=EN-GB style='color:black;background:#D9D9D9'>]</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>17.     UNIQUE IDENTIFIER  2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:silver'>2D barcode carrying the unique identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>18.     UNIQUE IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><span lang=EN-GB>PC: {number} </span></p>

<p class=MsoNormal><span lang=EN-GB>SN: {number}</span></p>

<p class=MsoNormal><span lang=EN-GB>NN: {number}</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Hepsera 10&nbsp;mg tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>Adefovir dipivoxil</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Read all of
this leaflet carefully before you start taking this medicine because it
contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        Keep this leaflet.  You may need to read it
again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        If you have any further questions, ask your
doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        This medicine has been prescribed for you
only.  Do not pass it on to others.  It may harm them, even if their signs of
illness are the same as yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-        If you get any side effects, talk to your
doctor or pharmacist.  This includes any possible side effects not listed in
this leaflet.  See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1.       What Hepsera is and what it is used for</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2.       What you need to know before you take Hepsera</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3.       How to take Hepsera</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4.       Possible side effects</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5.       How to store Hepsera</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6.       Contents of the pack and other information</span></p>

<p class=MsoNormal style='margin-right:-1.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1.       What Hepsera is and
what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Hepsera is</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepsera belongs
to a group of medicines called antiviral medicines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepsera is used
to treat chronic hepatitis&nbsp;B, an infection with hepatitis&nbsp;B virus
(HBV), in adults.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Infection with
the hepatitis&nbsp;B virus leads to damage to the liver.  Hepsera reduces the
amount of the virus in your body, and has been shown to reduce liver damage.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.       What you need to
know before you take Hepsera</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Hepsera</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>If you are allergic</span></b><span
lang=EN-GB> to adefovir, adefovir dipivoxil or any of the other ingredients of
this medicine (listed in section&nbsp;6).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Tell your doctor at once </span></b><span
lang=EN-GB>if you could be allergic to adefovir, adefovir dipivoxil or any of
the other ingredients of Hepsera.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor before using Hepsera.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Tell your doctor if you have had kidney
disease</span></b><span lang=EN-GB>, or if tests have shown problems with your
kidneys.  Hepsera can affect the way your kidneys work.  The risk of this
occurring is increased with long-term use of Hepsera.  Your doctor should run
tests to check your kidneys and liver are working properly, before and during
your treatment.  Depending on the results, your doctor may change how often you
take Hepsera.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are over 65&nbsp;years of age your doctor
may monitor your health more closely.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Dont stop taking Hepsera</span></b><span
lang=EN-GB> without your doctors advice.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>After stopping Hepsera tell your doctor
immediately</span></b><span lang=EN-GB> about any new, unusual or worsening
symptoms that you notice after stopping treatment.  Some patients have had
symptoms or blood tests indicating that their hepatitis has worsened after
stopping treatment with Hepsera.  Its best for your doctor to monitor your
health after stopping treatment with Hepsera.  You may need blood tests for
several months after treatment.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Once you start taking Hepsera:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>look out for possible signs of lactic
acidosis</span></b><span lang=EN-GB>  see&nbsp;section&nbsp;4, Possible side
effects.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>your doctor should order blood tests every
three months</span></b><span lang=EN-GB> to check your medicine is keeping your
chronic hepatitis&nbsp;B infection under control.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Take care not to infect other people.</span></b><span
lang=EN-GB>  Hepsera does not reduce the risk of passing on HBV to others
through sexual contact or blood contamination.  You must continue to take precautions
to avoid this.  A vaccine is available to protect those at risk from becoming
infected with HBV.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are HIV&nbsp;positive this medicine will
not control your HIV&nbsp;infection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Do not use Hepsera in children</span></b><span
lang=EN-GB> or adolescents under 18&nbsp;years of age.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Hepsera</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Do not take Hepsera if you are taking any
medicines containing tenofovir.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Tell your doctor or pharmacist</span></b><span
lang=EN-GB> if you are taking, have recently taken or might take any other medicines,
including medicines and herbal products obtained without a prescription.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>It is especially important to tell your
doctor</span></b><span lang=EN-GB> if you are taking or have recently taken any
of the following medicines which may damage your kidneys, or interact with
Hepsera:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>vancomycin and aminoglycosides, used for
bacterial infections</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>amphotericin&nbsp;B, for fungal infections</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>foscarnet, cidofovir or tenofovir disoproxil
fumarate, for viral infections</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:0in;
margin-left:56.7pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:normal'><span
lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>pentamidine, for other types of infection.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Hepsera with food and drink</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Hepsera can be taken with or without food.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy and breast-feeding</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
pregnant or breast-feeding, think you may be pregnant or are planning to have a
baby, ask your doctor or pharmacist for advice before taking this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Tell your doctor immediately if you are
pregnant</span></b><span lang=EN-GB> or planning to become pregnant.  It is not
known whether Hepsera is safe to use during human pregnancy.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Use an effective method of contraception</span></b><span
lang=EN-GB> to avoid becoming pregnant if you are a woman of child-bearing age
taking Hepsera.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Do not breast-feed while taking Hepsera.</span></b><span
lang=EN-GB>  It is not known whether the active substance in this medicine
passes into breast milk.</span></p>

<p class=MsoNormal style='line-height:normal'><s><span lang=EN-GB><span
 style='text-decoration:none'>&nbsp;</span></span></s></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Hepsera contains lactose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are
lactose-intolerant, or if you have been told that you have an intolerance to
some sugars, talk to your doctor before taking Hepsera.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.       How to take Hepsera</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Always take this
medicine exactly as your doctor has told you.</span></b><span lang=EN-GB>  This
is to make sure that your medicine is fully effective and to reduce the
development of resistance to the treatment.  Check with your doctor or pharmacist
if you are not sure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>The recommended dose</span></b><span
lang=EN-GB> is one 10&nbsp;mg tablet each day, taken with or without food.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>A different dose</span></b><span lang=EN-GB>
may be given to patients with <b>kidney problems</b>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you take more Hepsera than you should</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you
accidentally take too many Hepsera tablets, contact your doctor or nearest
hospital immediately.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you forget to take Hepsera or you vomit</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is important
not to miss a dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>If you do miss a dose</span></b><span
lang=EN-GB> of Hepsera, take it as soon as you can, and then take your next
scheduled dose at its regular time.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>If it is nearly time for your next dose,</span></b><span
lang=EN-GB> skip the missed dose.  Wait and take the next dose at the regular
time.  Do not take a double dose (two doses close together).</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>If you are sick (vomit) less than 1&nbsp;hour
after taking Hepsera</span></b><span lang=EN-GB> take another tablet.  You do
not need to take another tablet if you are sick more than 1&nbsp;hour after
taking Hepsera.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you stop taking Hepsera</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Tell your doctor immediately about any new, </span></b><span
lang=EN-GB>unusual or worsening symptoms that you notice after stopping
treatment.  See&nbsp;section&nbsp;2 for more details.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Dont stop taking Hepsera</span></b><span
lang=EN-GB> without your doctors advice.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have any further
questions on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.       Possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Like all
medicines, this medicine can cause side effects, although not everybody gets
them.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Very rare side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>(These can affect less than 1 in 10,000&nbsp;people taking Hepsera)</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Lactic acidosis is a serious but very rare
side effect of taking Hepsera.</span></b><span lang=EN-GB>  It can cause too
much lactic acid in the blood and enlargement of the liver.  Lactic acidosis
occurs more often in women, particularly if they are very overweight.  People
with liver disease may also be at risk.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Some of the signs of lactic acidosis are:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Feeling sick (nausea) and sickness (vomiting)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stomach pain</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
style='font-family:Wingdings'>à</span><b><span lang=EN-GB>Contact your doctor
at once</span></b><span lang=EN-GB> if you get any of these symptoms.  They are
the same as some of the common side effects of Hepsera.  If you do get any of
them, it is unlikely to be serious, but you need to check.  Your doctor will
monitor you regularly while you take Hepsera.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Common side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>(These can affect 1 to 10 in every 100&nbsp;people taking Hepsera)</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Headache</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Feeling sick (nausea)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Diarrhoea</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Digestive problems including wind or discomfort
after eating meals</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Stomach pain</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kidney problems, as shown by blood tests</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
style='font-family:Wingdings'>à</span><span lang=EN-GB>Tell a doctor or
pharmacist if you are worried about any of these.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Very common side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>(These can affect more than 10 in every 100&nbsp;people taking
Hepsera)</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Weakness</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
style='font-family:Wingdings'>à</span><span lang=EN-GB>Tell a doctor or
pharmacist if you are worried about this.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Side effects before or after having a liver transplant</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Some patients have experienced:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Rash and itching  common</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Feeling sick (nausea) or being sick (vomiting) 
common</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kidney failure  common</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kidney problems  very common</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
style='font-family:Wingdings'>à</span><span lang=EN-GB>Tell a doctor or pharmacist
if you are worried about any of these.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Also tests may show decreases in phosphate
(common) or increases in creatinine (very common) in the blood.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other possible side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Some patients may also experience:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kidney failure</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Damage to kidney tubule cells</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Kidney problems may lead to softening of the
bones (which causes bone pain and sometimes leads to fractures) and muscle pain
or weakness.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Inflammation of the pancreas (pancreatitis)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>If you get any side effects, talk to your doctor or pharmacist.</span><span
lang=EN-GB>  This includes any possible side effects not listed in this
leaflet.  You can also report side effects directly via <span style='color:
black;background:#D9D9D9'>the national reporting system listed in <a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:black;text-decoration:none'>Appendix&nbsp;V</span></a></span>.  By
reporting side effects you can help provide more information on the safety of
this medicine.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>5.       How to store Hepsera</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use this
medicine after the expiry date which is stated on the bottle and carton after {EXP}. 
The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not store
above 30ºC (86ºF).  Store in the original package in order to protect from
moisture.  Keep the bottle tightly closed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Return any left
over tablets to your pharmacist.  Only keep them if your doctor tells you to.  Do
not throw away any medicines via wastewater or household waste.  Ask your
pharmacist how to throw away medicines you no longer use.  These measures will
help protect the environment.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.       Contents of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Hepsera contains</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>The active substance</span></b><span
lang=EN-GB> in Hepsera is adefovir dipivoxil.  Each tablet contains 10&nbsp;mg
adefovir dipivoxil.</span></p>

<p class=MsoNormal style='margin-left:27.0pt;text-indent:-27.0pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>The other ingredients are: pregelatinised
starch, croscarmellose sodium, lactose monohydrate, talc and magnesium
stearate.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Hepsera looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hepsera
10&nbsp;mg tablets are round, white to off&#8209;white tablets.  The tablets
are marked with GILEAD and 10 on one side and a stylised shape of a liver
on the other side.  Hepsera 10&nbsp;mg tablets are supplied in bottles of
30&nbsp;tablets with silica gel desiccant.  The silica gel desiccant is
contained in either a separate sachet or a small canister and should not be
swallowed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
pack sizes are available: outer cartons containing 1&nbsp;bottle of
30&nbsp;tablets and outer cartons containing 90 (3&nbsp;bottles of
30)&nbsp;tablets.  Not all pack sizes may be marketed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder and Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Gilead Sciences Ireland UC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Carrigtohill</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>County Cork, T45 DP77</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Gilead Sciences Ireland UC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>IDA Business &amp; Technology Park</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Carrigtohill</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>County Cork</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>België/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Belgium SPRL-BVBA</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tél/Tel: + 32
  (0) 24 01 35 50</span></p>
  <p class=MsoNormal style='margin-right:1.7pt;line-height:normal'><span
  lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 48 22
  262 8702</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  + 353 (0) 1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Belgium SPRL-BVBA</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tél/Tel: + 32
  (0) 24 01 35 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#268;eská
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: </span><span
  lang=EN-GB>+ 420 (0) 910 871 986</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Magyarország</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences </span><span lang=EN-GB>Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tlf: + 46 (0)
  8 5057 1849</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences </span><span lang=EN-GB>Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 49 (0)
  89 899890-0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Netherlands B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 31 (0)
  20 718 36 98</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 48 22
  262 8702</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tlf: + 46 (0)
  8 5057 1849</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences &#917;&#955;&#955;&#940;&#962; &#924;.&#917;&#928;&#917;.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#932;&#951;&#955;:
  + 30 210 8930 100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Österreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences GesmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 43 1
  260 830</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>España</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences, S.L.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 34 91
  378 98 30</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead Sciences
  Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 48 22
  262 8702</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tél: + 33 (0)
  1 46 09 41 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences, Lda.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 351 21
  7928790</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><b><span
  lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Gilead Sciences </span><span lang=EN-GB>Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>România</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences </span><span lang=EN-GB>Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  1 686 1888</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  214 825 999</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences </span><span lang=EN-GB>Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ísland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sími: + 46 (0)
  8 5057 1849</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovenská
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 421 (0)
  232 121 210</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences S.r.l.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 39 02
  439201</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Puh/Tel: + 46
  (0) 8 5057 1849</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences &#917;&#955;&#955;&#940;&#962; &#924;.&#917;&#928;&#917;.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#932;&#951;&#955;:
  + 30 210 8930 100</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 46 (0)
  8 5057 1849</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><a name="OLE_LINK1"></a><a
  name="OLE_LINK2"><span lang=EN-GB>Gilead Sciences Poland Sp. z o.o.</span></a></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 48 22
  262 8702</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ltd</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 44 (0) 8000
  113 700</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-right:-22.45pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>This leaflet was last revised in {MM/YYYY}.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: </span><span lang=EN-GB>http://www.ema.europa.eu</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This leaflet is
available in all EU/EEA languages on the European Medicines Agency website.</span></p>

</div>

</body>

</html>
